Skip to main content

Table 2 Summary of clinicopathologic and outcome data of patients with fibrolamellar carcinoma collected from the literature

From: Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments

Author TP YP Total number of patients ♂:♀ Age CD % AFP↑ LR % LT % 5y-OS %, LR 5y-OS %, LT DR % 5y-DSF % 5y-OS %
Craig et al. [8] 1918–1973 1980 23 1:1 26 None 0/6 48 None nr na nr nr nr (32)
Nagorney et al. [9] 1950–1982 1985 16 1.3:1 26 None 1/6 75 None nr na 75 42 50
Berman et al. [17] 1981–1987 1988 19 2.2:1 25 None 4/15 63 26 nr nr 59 nr nr (37)
Wood et al. [51] 1960–1983 1988 15 1:2.8 26 None 3/9 60 None 45 na nr nr 45 (32)
Iwatsuki et al. [68] 1980–1989 1991 22 nr nr nr nr 55 45 65 38 nr nr nr
Ringe et al. [1] 1974–1988 1992 20 1.2:1 23 None 0/18 70 30 40 (45) nr (29) 60 29 37 (45)
Pinna et al. [2] 1968–1995 1997 41 1.3:1 30 7 2/19 68 32 75 36 66 33 66 (127)
Epstein et al. [30] 1985–1990 1999 17 1:1 24 None 0/16 None None na na nr na nr (14)
El-Gazzaz et al. [3] 1985–1998 2000 20 1:1.9 27 None 0/20 55 45 65 50 45 50 50 (62)
Ichikawa et al. [14] 1989–1997 2000 40 1:1.2 29 None 3/40 62 10 nr nr 71 nr nr
El-Serag and Davila [4] 1986–2000 2004 68 1:1 33 nr nr nr nr nr nr nr nr 37
Kakar et al. [10] 1987–2000 2005 20 1:1 27 None 3/13 nr nr nr nr nr nr 45
Moreno-Luna et al. [5] 1990–2003 2005 15 nr nr nr nr 80 None nr na nr nr 26
Stipa et al. [6] 1986–2003 2006 41 1:1.4 27 None 3/41 68 None 76 na 61 18 76 (112)
Malouf et al. [23] 1987–2007 2012 40 0.3:1 22 3 7/40 100 None 58 na 58 37 58
Mavros et al. [11] 1963–2008 2012 575 1:1.1 21 3 27/266 55 23 70 (222) 34 (32) 33–100 nr 44 (39)
Ang et al. [58] 1986–2011 2013 95 0.7:1 22 nr 3/31 73 4 nr nr 77 nr nr
Kaseb et al. [7] 1992–2008 2013 94 1:1 23 6 13/94 59 2 nr nr 84 nr 46 (57)
Eggert et al. [69] 2000–2010 2013 191 1.7:1 nr nr nr 41 46 58 57 nr nr 34
Groeschl et al. [12] 1993–2010 2014 35 1.7:1 39 14 1/35 100 None 62 na 50 45 62 (174)
Darcy et al. [15] 1981–2011 2015 25 1:1.3 17 None 2/25 84 None 52 na 63 nr 43
  1. TP time period, YP year of publication, ♂:♀ male to female ratio, CD number of patients with chronic liver disease particularly liver cirrhosis in percent of the total number of patients, AFP↑ number of patients with pathologic elevation of alpha-fetoprotein in relation to tested patients, LR liver resection, LT liver transplantation, 5y-OS 5-year overall survival (numbers in bracket indicate the average survival in months for any treatment), DR disease recurrence, DSF disease free survival, nr not reported, na not applicable